European CHMP Confirms Negative Opinion on Bronchotol for Cystic Fibrosis
Release Date: 24/06/2011 12:00am
Pharmaxis today announced it has been advised by the European Medicines Agency that the June meeting of the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion in relation to the Company's marketing application for Bronchitol for cystic fibrosis.This confirms the negative trend vote, taken by the CHMP at its May meeting that was advised by Pharmaxis on 25 May 2011.
The Company expects to receive further information and will update the market as appropriate.
Categories: News and Media